Tag: diabetes

Type 1 Diabetes Has Never Had a Disease-Modifying Therapy That Works After Diagnosis. Tzield Just Changed That. Here Is What the PROTECT Trial Data Shows.

The essentials: On June 12, 2026 (announced June 13), the FDA granted accelerated approval to Tzield (teplizumab-mzwv, Sanofi) for a new indication: to delay the decline in endogenous (the patient’s own) insulin production in pediatric patients aged 8 through 17 years recently diagnosed with Stage 3 type 1 diabetes (T1D). This is the first FDA-approved disease-modifying therapy for recently diagnosed Stage 3 type 1 diabetes. Prior to this approval, there was no treatment capable of altering the course of T1D after clinical diagnosis. Critical time window: treatment must be initiated within 8 weeks of Stage 3 T1D diagnosis. This is an acute clinical opportunity: families and pediatric endocrinologists need to be aware that this window exists and act accordingly. Regulatory pathway: accelerated approval based on C-peptide (a surrogate marker of beta-cell function reasonably likely to predict clinical benefit). A post-approval confirmatory study, the Phase 3 BETA-PRESERVE trial, is ongoing. The clinical basis: Phase 3 PROTECT trial (NCT03875729), 328 youth with Stage 3 T1D enrolled within 6 weeks of diagnosis. Two 12-day IV infusion courses (at baseline and at week 26). Primary endpoint: stimulated C-peptide AUC at 78 weeks, a validated surrogate of beta-cell function. Teplizumab significantly preserved C-peptide versus placebo at 78 weeks. Clinically meaningful beta-cell function maintained in 94.9% of teplizumab-treated patients versus 79.2% of controls. Supporting outcomes: better HbA1c, more time-in-range, less insulin use, and lower hypoglycemia favored teplizumab numerically, though without statistical significance for each. Tzield is not effective as a disease-modifying therapy in non-autoimmune dysglycemic conditions: it only works when the underlying cause is immune-mediated beta-cell destruction. Key safety warnings: cytokine release syndrome (CRS), lymphopenia, viral reactivation including EBV and CMV (most serious cases in patients who continued treatment despite persistent severe lymphopenia). Tzield’s complete indication picture after June 2026: Stage 2 T1D (delay of Stage 3 onset) in patients aged 1 year and older; Stage 3 T1D (delay of insulin production decline) in patients aged 8 to 17 years recently diagnosed.

Type 1 diabetes is an autoimmune disease in which the immune system destroys the insulin-producing beta cells of the pancreas. For almost the entirety of its known history, nothing in medicine could change that course after it began. Insulin was discovered in 1921 and saved countless lives, but it did not address the underlying immune attack. Immunosuppressive agents reduced beta-cell destruction in small studies but caused unacceptable side effects. The disease progressed. Eventually, the beta cells were gone.

Teplizumab (Tzield) was the first drug to change any part of that story. Its original approval in November 2022 for Stage 2 T1D (the pre-symptomatic stage, before diagnosis) demonstrated that a 14-day course of IV treatment could delay the onset of clinical diabetes by approximately two years in at-risk individuals. That was extraordinary. But it left open a question: what about the children who were already diagnosed?

On June 12, 2026, the FDA answered that question. Tzield received accelerated approval for use after diagnosis, specifically to delay the decline of the patient’s own insulin production in children and adolescents aged 8 to 17 who have been recently diagnosed with Stage 3 T1D. It is the first disease-modifying therapy ever approved for recently diagnosed type 1 diabetes. There has never been anything like it before.

This post covers the staged model of type 1 diabetes and why it matters clinically, how teplizumab’s CD3 mechanism works to modulate the autoimmune attack, what the PROTECT trial showed, what the accelerated approval pathway means for the evidence base, what the 8-week treatment window requires from families and clinicians, and what this approval means for the type 1 diabetes community.

The Staged Model of Type 1 Diabetes: Why the Stage Matters

Type 1 diabetes is not a single event. It is a continuum of progressive autoimmune destruction of pancreatic beta cells that begins years before clinical diagnosis and continues afterward. The staged model, developed by the American Diabetes Association and JDRF (now Breakthrough T1D), provides a framework that has reshaped how clinicians and researchers understand and now treat the disease.

Stage	Definition	What it means clinically
Stage 1 T1D	Two or more positive islet autoantibodies; normoglycemia; no symptoms	Beta-cell autoimmunity established; at high risk for progression; no metabolic dysfunction yet
Stage 2 T1D	Two or more positive islet autoantibodies; dysglycemia (glucose abnormalities without meeting diabetes criteria); no symptoms	Beta-cell loss accelerating; progression to Stage 3 virtually certain without intervention; Tzield approved here (Stage 2 in patients aged 1 year and older)
Stage 3 T1D	Two or more positive autoantibodies plus symptomatic hyperglycemia meeting diabetes diagnostic criteria	Clinical diabetes: the stage families recognize as “diagnosis.” Beta-cell function still partially preserved at this point; Tzield now approved here in patients aged 8 to 17 years recently diagnosed

The critical insight embedded in this staging model, and the reason the June 2026 approval matters so much, is that Stage 3 T1D does not begin with zero remaining beta cells. At the time of clinical diagnosis, a meaningful fraction of insulin-producing capacity is still present. The autoimmune attack has been ongoing for years, but it has not yet completed its work. There is a window, measured in weeks to months after clinical diagnosis, during which intervention to slow or interrupt the immune destruction of the remaining beta cells is still biologically possible and clinically meaningful.

That window is exactly what teplizumab’s new indication targets.

Why preserving residual beta-cell function matters clinically Even partial preservation of the patient’s own insulin production, measured as C-peptide secretion, translates into tangible clinical advantages that insulin therapy alone cannot replicate. Patients with measurable residual beta-cell function consistently show better HbA1c levels, more time in glycemic range, lower insulin requirements, and meaningfully reduced frequency of severe hypoglycemia compared to patients with no endogenous insulin production. The pancreas’s own insulin secretion is exquisitely responsive to real-time blood glucose fluctuations in a way that no external insulin replacement strategy, including advanced closed-loop systems, can fully replicate. This is the clinical rationale for C-peptide preservation as both a trial endpoint and a treatment goal: it is not an abstract biomarker. It is a direct predictor of quality of life, safety, and long-term diabetes outcomes.

How Teplizumab Works: The CD3 Mechanism

Teplizumab is a humanized monoclonal antibody that targets CD3, a protein complex on the surface of T cells. Understanding why blocking CD3 helps preserve beta cells requires a brief look at the immunology of type 1 diabetes.

In type 1 diabetes, autoreactive CD8+ cytotoxic T cells and CD4+ helper T cells infiltrate the pancreatic islets and selectively destroy the beta cells that produce insulin. These T cells recognize beta-cell antigens (such as glutamic acid decarboxylase and insulin itself) as foreign and mount a sustained immune attack. The attack is not a single event; it is an ongoing, progressive destruction that continues over years and accelerates toward the time of clinical diagnosis and beyond.

CD3 is a component of the T-cell receptor complex: it is the intracellular signaling module that transduces the activation signal when a T cell’s antigen receptor binds its target. By binding CD3, teplizumab modulates T-cell activation without completely eliminating T cells from the circulation. This partial modulation is important: unlike conventional immunosuppressants that broadly suppress all T cell activity (creating broad susceptibility to infection), teplizumab’s mechanism selectively tolerizes the autoreactive T cells most responsible for beta-cell destruction while preserving broader immune function.

The proposed mechanism includes several complementary effects: induction of partially exhausted or tolerogenic T cells that suppress the autoimmune response; preferential depletion of effector T cells in the inflamed islets; and expansion of regulatory T cells that actively suppress autoimmunity. The net result, observed in both the original Stage 2 trials and now in the Stage 3 PROTECT trial, is a slower rate of beta-cell destruction measurable as preserved C-peptide secretion over years of follow-up after the treatment is complete.

Teplizumab is administered as a 14-day intravenous infusion course, not as an ongoing therapy. Two courses are given: one at baseline (treatment initiation) and one at week 26 (6 months later). After that, no further doses are required. The immune reprogramming established by the two courses appears to produce durable benefit, as evidenced by the persistent C-peptide preservation observed in PROTECT through 78 weeks after enrollment.

The PROTECT Trial: What the Evidence Shows

Design

PROTECT (NCT03875729) was a Phase 3, randomized, double-blind, placebo-controlled multinational trial specifically designed to evaluate teplizumab in newly diagnosed Stage 3 T1D. The trial enrolled 328 children and adolescents (teplizumab n=217, placebo n=111) within 6 weeks of Stage 3 T1D diagnosis.

Treatment regimen: Two 12-day intravenous infusion courses of teplizumab or placebo: one at baseline and one at week 26, in addition to standard diabetes care (insulin therapy and glucose monitoring).

Primary endpoint: Stimulated C-peptide area under the curve (AUC) at 78 weeks, measured during a mixed meal tolerance test (MMTT). C-peptide is co-secreted with insulin from beta cells; its level in the blood is a direct measure of functional beta-cell mass, unaffected by exogenous insulin administration.

Primary endpoint results

Teplizumab significantly preserved stimulated C-peptide versus placebo at 78 weeks. C-peptide is a validated surrogate endpoint for beta-cell function that is reasonably likely to predict clinical benefit, which is the evidentiary standard for accelerated approval.

Secondary and supporting outcomes

Outcome	Teplizumab	Placebo	Notes
Clinically meaningful beta-cell function maintained at 78 weeks	94.9%	79.2%	Clinically significant difference; higher proportion preserved residual function
HbA1c	Numerically favored teplizumab	Reference	Did not reach statistical significance
Time in range	Numerically favored teplizumab	Reference	Did not reach statistical significance
Insulin dose	Numerically lower with teplizumab	Reference	Did not reach statistical significance
Hypoglycemia	Numerically lower with teplizumab	Reference	Did not reach statistical significance

Source: Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and beta-cell function in newly diagnosed type 1 diabetes. NEJM. 2023;389(23):2151–2161. doi:10.1056/NEJMoa2306691. PROTECT NCT03875729.

The finding that 94.9% of teplizumab-treated patients maintained clinically meaningful beta-cell function compared to 79.2% of controls at 78 weeks is clinically important. It means that a substantially higher proportion of treated children preserved enough of their own insulin production to realize the downstream glycemic benefits associated with residual beta-cell function.

The secondary outcome numerical trends (better HbA1c, more time in range, less insulin needed, less hypoglycemia) are directionally consistent with what prior research has shown about the clinical value of C-peptide preservation, even without reaching individual statistical significance. They support the clinical plausibility of the C-peptide surrogate endpoint.

Dr. Kevan Herold, MD, C.N.H. Long Professor of Immunobiology and Medicine at Yale School of Medicine and co-author of the PROTECT trial, has stated that practically all patients with new-onset Stage 3 T1D should be offered therapy unless there is an underlying condition that would prevent drug administration, describing the absence of other disease-modifying alternatives for T1D as the defining context for this recommendation.

The accelerated approval basis and confirmatory study

The FDA granted this approval under the accelerated approval pathway, based on C-peptide as a surrogate endpoint reasonably likely to predict clinical benefit. This is the same pathway used for many rare disease and serious condition approvals where waiting for long-term clinical outcome data would delay access to potentially beneficial therapies.

The BETA-PRESERVE trial (NCT05902884), a Phase 3 confirmatory study, is ongoing to verify the clinical benefit of C-peptide preservation in terms of direct patient outcomes including HbA1c, time in range, insulin requirements, and hypoglycemia frequency. Continued approval is contingent on the confirmatory study verifying this clinical benefit.

The 8-Week Treatment Window: What This Means Practically

The approved indication specifies patients recently diagnosed with Stage 3 T1D. Breakthrough T1D has clarified this as within the last 8 weeks of Stage 3 diagnosis. This is not an administrative convenience: it is a biological reality. The earlier treatment is initiated after clinical diagnosis, the more residual beta-cell function remains to preserve. Waiting months after diagnosis substantially reduces the potential benefit.

This 8-week window creates a specific and urgent clinical requirement: families and pediatric endocrinologists must be aware of Tzield’s availability at the time of diagnosis, not months later. For families receiving a new T1D diagnosis in a child or adolescent, this means:

Ask the diagnosing pediatric endocrinologist at the initial appointment whether Tzield is appropriate for your child
If your child is aged 8 to 17, was diagnosed within the past 8 weeks, and has confirmed autoimmune T1D, the conversation about Tzield should happen now, not at the 3-month follow-up visit
A referral to an academic center or JDRF-connected care team with experience in disease-modifying therapy may be appropriate if the diagnosing center is not yet familiar with the treatment protocol

The two 12-day IV infusion courses require IV access and monitoring during infusions, which means this is not a home therapy. It requires an infusion center or hospital setting, coordination of insurance authorization, and scheduling. These logistics take time, making awareness at diagnosis critical for staying within the treatment window.

Tzield’s Complete Indication Picture After June 2026

Two approvals and one significant expansion have occurred in 2026:

Indication	Population	Approval date
Delay onset of Stage 3 T1D	Adults and pediatric patients aged 1 year and older with Stage 2 T1D	November 2022 (original); expanded to ages 1 to 7 in April 2026 (previously 8 and older)
Delay decline in insulin production in recently diagnosed Stage 3 T1D	Pediatric patients aged 8 to 17 years within 8 weeks of Stage 3 T1D diagnosis	June 12, 2026 (accelerated approval)

The Stage 2 expansion to children as young as 1 year (April 2026, based on PETITE-T1D study data) and the Stage 3 approval (June 2026, PROTECT) together mean that teplizumab is now available across the full spectrum of high-risk and newly diagnosed pediatric T1D, from presymptomatic at-risk toddlers through adolescents at clinical diagnosis.

Safety: What the Prescribing Information and Trial Data Show

Teplizumab’s safety profile is driven by its mechanism of CD3-directed T-cell modulation during 12-day IV infusion courses. The adverse event profile in PROTECT was consistent with the previously characterized teplizumab dataset from over 900 patients across the development program.

Warnings and key adverse events:

Cytokine release syndrome (CRS): A class effect of CD3-directed therapies. CRS occurs during the infusion course and is characterized by fever, nausea, headache, fatigue, myalgia, and other systemic symptoms. In teplizumab trials, CRS is generally mild to moderate and managed with premedication (acetaminophen and antihistamines) and supportive care during infusion. Severe CRS has been reported and requires prompt management. Infusion settings must be equipped to manage CRS.

Lymphopenia: T-cell depletion is expected with teplizumab and is part of its mechanism. Severe lymphopenia requires close monitoring. The most serious viral reactivation events observed in the clinical program occurred in patients who continued therapy despite persistent, severe lymphopenia. Current guidance requires dose interruption or discontinuation in the setting of persistent severe lymphopenia.

Viral reactivation: Serious, life-threatening cases of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation have been reported. Most serious cases occurred in patients with persistent, severe lymphopenia who continued treatment. Viral reactivation surveillance before and during treatment is essential.

Other adverse events reported in PROTECT: Lymphopenia (expected), cytopenias (reductions in other blood cell types), gastrointestinal symptoms, rash, transaminase elevations, and headache. These were generally consistent with the expected immunomodulatory effects of the drug.

Pre-treatment requirements:

Screening for EBV and CMV serostatus before initiating treatment
Complete blood count monitoring before and during treatment courses
Premedication before infusions to reduce CRS severity
Avoid live vaccines during and after treatment until lymphocyte recovery is confirmed

Contraindications:

Active serious infection
Immunocompromised patients are at increased risk; careful benefit-risk assessment required
Tzield is not effective as a disease-modifying therapy in non-autoimmune dysglycemic conditions: laboratory confirmation of autoimmune etiology (positive islet autoantibodies) is a clinical prerequisite

What This Means for Families and Clinicians

For families of a child recently diagnosed with T1D

If your child is aged 8 to 17 and has been diagnosed with type 1 diabetes within the past 8 weeks, Tzield is now an FDA-authorized option that deserves immediate discussion with your pediatric endocrinologist. This is not a therapy to consider “later.” The 8-week window is real and it closes.

Questions to ask your endocrinology team:

Has my child had autoantibody testing that confirms autoimmune T1D?
Are we within 8 weeks of diagnosis?
Is Tzield appropriate for my child given their health history?
Where can we receive the infusion courses?
What is the prior authorization process with our insurance?

The Breakthrough T1D website and JDRF Tzield resources provide current information for families navigating this decision. Sanofi’s Tzield support program (1-800-633-1610) provides information about access, insurance navigation, and referral to treatment centers.

For pediatric endocrinologists

This approval creates a new, urgent clinical protocol: at the time of Stage 3 T1D diagnosis in any patient aged 8 to 17, the Tzield conversation should occur within the first visit or at minimum within the first week of diagnosis. This is the same urgency model used for conditions like acute lymphoblastic leukemia, where initiating disease-modifying treatment in the correct window fundamentally alters long-term outcomes.

The treatment infrastructure requirements (IV infusion over 12 consecutive days, monitoring for CRS and lymphopenia, EBV/CMV screening) mean that systems-level readiness at pediatric endocrinology centers is important. Centers not currently equipped to administer teplizumab should establish referral pathways to centers that are.

The broader significance

Dr. Aaron J. Kowalski, PhD, CEO of Breakthrough T1D, described the approval as providing “a novel therapy that targets the autoimmune and progressive nature of stage 3 type 1 diabetes,” noting that approximately 64,000 people are diagnosed with T1D every year in the United States. For the pediatric portion of that population, a brief window of opportunity now exists to alter the course of the disease in a way that was not previously possible.

Type 1 diabetes has been managed for over 100 years with increasingly sophisticated insulin replacement. This is the first time a treatment has been approved that goes beyond replacement to address the underlying autoimmune destruction. It is a genuinely historic moment for the T1D community.

For related HED coverage on other disease-modifying therapies and autoimmune conditions, see our post on Ocrevus (ocrelizumab) receiving pediatric approval for relapsing-remitting multiple sclerosis, another CD20-directed therapy that alters the course of an autoimmune disease, and our post on Awiqli, the first once-weekly basal insulin for type 2 diabetes, for context on how the insulin therapy landscape continues to evolve alongside disease-modifying approaches.

Sources

FDA approval announcement: FDA approves new indication for Tzield (teplizumab) for certain pediatric patients with recently diagnosed Stage 3 type 1 diabetes. FDA.gov. June 12 (announced June 15), 2026.

Sanofi press release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes. Sanofi. June 12, 2026.

Drugs.com approval news: Sanofi’s Tzield Approved in the US as the First Disease-Modifying Therapy for Patients Recently Diagnosed with Stage 3 Type 1 Diabetes. drugs.com. June 13, 2026.

FDA plain language summary: FDA approves drug for pediatric stage 3 type I diabetes. FDA.gov. June 2026.

Pharmacy Times clinical review: FDA Approves Teplizumab-mzwv for Children With Newly Diagnosed Stage 3 Type 1 Diabetes. pharmacytimes.com. June 2026.

Patient Care Online clinical summary (with investigator cautions): FDA Expands Teplizumab Approval for Pediatric Stage 3 Type 1 Diabetes. patientcareonline.com. June 2026.

Healio endocrinology coverage: FDA approves Tzield to treat children and adolescents with stage 3 type 1 diabetes. healio.com. June 2026.

Pediatric Endocrine Society clinical summary: Teplizumab Approval Expanded to Stage 3 Type 1 Diabetes (Ages 8-17). pedsendo.org. June 2026.

Breakthrough T1D community update: Tzield approved for stage 3 T1D in the U.S. breakthrought1d.org. June 2026.

BioPharm International coverage: FDA Expands Pfizer’s Hympavzi Approval… (note: cross-reference; not directly cited for Tzield)

Sanofi Stage 2 expansion (April 2026, ages 1-7): Sanofi’s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children. sanofi.com. April 22, 2026.

PROTECT trial primary publication: Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and beta-cell function in newly diagnosed type 1 diabetes. NEJM. 2023;389(23):2151–2161. doi:10.1056/NEJMoa2306691.

PROTECT trial registration: NCT03875729. ClinicalTrials.gov.

BETA-PRESERVE confirmatory trial registration: NCT05902884. ClinicalTrials.gov.

Teplizumab mechanism review: Teplizumab in Type 1 Diabetes. PMC9356435.

T1D staging scientific statement: Staging Presymptomatic Type 1 Diabetes. Diabetes. 2015;64(8):2541–2550.

T1D StatPearls: Type 1 Diabetes Mellitus. StatPearls. NCBI.

NIDDK T1D overview: Type 1 Diabetes. NIDDK.

Accelerated approval pathway: Accelerated Approval. FDA.gov.

EBV: Epstein-Barr Virus. StatPearls. NCBI.

CMV: Cytomegalovirus. StatPearls. NCBI.

Tzield prescribing information: TZIELD (teplizumab-mzwv) Prescribing Information. Sanofi. 2026.

Patient resources: Breakthrough T1D (JDRF) | American Diabetes Association: Type 1 | Sanofi Tzield patient support: 1-800-633-1610 | NIDDK Type 1 Diabetes

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Tzield (teplizumab-mzwv) is indicated for recently diagnosed Stage 3 T1D in pediatric patients aged 8 to 17 years within 8 weeks of diagnosis. It is not effective in non-autoimmune dysglycemic conditions. Treatment requires IV infusion and monitoring in a qualified clinical setting. Families should consult with a board-certified pediatric endocrinologist immediately after a child’s Stage 3 T1D diagnosis to determine eligibility and timing within the treatment window.

June 25, 2026

Januvia Has Been One of the Most Prescribed Diabetes Drugs in America for Nearly 20 Years. At $600 a Month With No Generic, Millions of Patients Could Not Afford It. That Is Finally Changing in 2026.

The essentials: Januvia (sitagliptin, Merck) is an oral DPP-4 inhibitor approved in October 2006 for the treatment of type 2 diabetes as monotherapy and as add-on combination therapy. Nearly 8 million Januvia prescriptions were filled in the United States in 2022 alone. Combined franchise sales with Janumet and Janumet XR exceeded $2 billion annually as recently as 2023. Retail price without insurance: approximately $600 to $700 per month. Generic timeline: Merck’s core sitagliptin patent expires November 24, 2026. Settlement agreements with more than 21 generic manufacturers allow launches as early as May 2026 under certain conditions. A generic sitagliptin phosphate (Viatris/Watson Labs) was approved December 30, 2025. Additionally, Zituvio (sitagliptin free base, Zydus), a different chemical form of sitagliptin that is not substitutable for Januvia at the pharmacy counter but can be prescribed specifically, has been available at select specialty pharmacies for approximately $80 per month since its October 2023 FDA approval. Expected generic price once multiple manufacturers are in the market: 80 to 85% below brand list price, approximately $80 to $100 per month. Janumet generics expected by May 2026; Janumet XR generics by July 2026, per settlement terms. Cardiovascular safety: the TECOS trial (n=14,671) established cardiovascular non-inferiority to placebo (HR 0.98; 95% CI 0.89 to 1.08; p less than 0.001 for non-inferiority). Sitagliptin did not increase heart failure hospitalizations in TECOS, a finding that distinguishes it from saxagliptin within the DPP-4 class. Sitagliptin does not have cardiovascular or cardiorenal protective indications.

📚 About this series: the 2026 Loss of Exclusivity Watch This is Post 4 of HED’s 2026 Loss of Exclusivity series, tracking the ten major drugs losing U.S. exclusivity this year. The full series covers: Xolair (omalizumab) • Pomalyst (pomalidomide) • Opsumit (macitentan) • Januvia/Janumet (sitagliptin) • Simponi (golimumab) • Mavenclad (cladribine) • Gattex (teduglutide) • Trintellix (vortioxetine) • Briviact (brivaracetam) • Xeljanz (tofacitinib). Each post follows the same format: what the drug is and how it works, what the clinical evidence shows, who uses it and why, and what the entrance of competition means for patients, prescribers, and the market.

Type 2 diabetes is one of the most common chronic conditions in the United States. Roughly 38 million Americans have diabetes, and about 90 to 95% of those cases are type 2. Managing it requires lifelong medication for most patients, typically starting with metformin and expanding to one or more additional agents as the disease progresses. The medication decisions made at each step affect not just blood sugar numbers, but long-term risks of kidney disease, nerve damage, heart attack, stroke, and blindness.

Januvia (sitagliptin) has been a cornerstone of type 2 diabetes management since its FDA approval in October 2006. Its combination of proven efficacy, low hypoglycemia risk, weight neutrality, and once-daily oral dosing made it a clinically attractive option for many patients. Nearly 8 million Januvia prescriptions were filled in the United States in 2022 alone, and its combined franchise with Janumet and Janumet XR generated over $2 billion in annual global sales as recently as 2023.

Its major limitation has been cost. At $600 to $700 per month retail with no widely available true generic, affordability has been a significant barrier for the millions of patients who take it.

That is changing. Merck’s core sitagliptin patent expires November 24, 2026, and settlement agreements with more than 21 generic manufacturers may allow generic sitagliptin to enter the market as early as May 2026 under certain conditions. Generic sitagliptin is expected to cost 80 to 85% less than brand-name Januvia once multiple manufacturers are competing.

This post covers what sitagliptin is, how DPP-4 inhibition works at a molecular level, what the clinical evidence shows about its efficacy and cardiovascular safety (including a nuanced story about heart failure that is often misunderstood), where it fits in the 2026 diabetes treatment landscape, and what the arrival of generics means for patients who have been caught between a drug that works and a price that does not.

A Brief History: How Sitagliptin Changed Diabetes Medicine

When the FDA approved Januvia in October 2006, it introduced a genuinely new class of diabetes medication. DPP-4 inhibitors worked through a mechanism that none of the existing oral agents — metformin, sulfonylureas, thiazolidinediones — shared: they amplified the body’s own hormonal response to meals rather than directly stimulating insulin secretion or reducing insulin resistance.

The clinical profile that emerged from trials was distinctive. Sitagliptin lowered blood sugar meaningfully but without causing hypoglycemia on its own, because its mechanism is glucose-dependent. It was weight neutral, a meaningful advantage over insulin and many other agents. It was well tolerated. And it came in a single once-daily pill with no food restrictions.

Five DPP-4 inhibitors, including sitagliptin, vildagliptin, alogliptin, saxagliptin, and linagliptin, were approved by regulatory authorities and entered the market between 2006 and 2013. For a decade, DPP-4 inhibitors became one of the most commonly prescribed second-line diabetes medication classes in the world. Januvia, as the first and best-known entry, captured the largest share of that market.

Merck generated roughly $50 billion in cumulative global Januvia sales over nearly two decades. The company has told investors it expects sales to drop substantially following generic launches, with research suggesting a drug’s price can fall as much as 20% when the first generic enters and as much as 85% after multiple alternatives are established.

The Science: How DPP-4 Inhibition Works

Understanding what sitagliptin does requires a brief explanation of the incretin system, one of the body’s core mechanisms for managing blood sugar after meals.

When you eat, specialized cells in the small intestine release hormones called incretins, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones signal the pancreas to increase insulin secretion and, in the case of GLP-1, to suppress glucagon (the hormone that raises blood sugar). The incretin effect amplifies the body’s insulin response to a meal in a glucose-dependent way: it only activates significantly when blood sugar is actually elevated.

The problem in type 2 diabetes is that this incretin response is blunted: both GLP-1 levels and the pancreatic response to incretins are diminished. And even what GLP-1 is released gets destroyed quickly. The enzyme dipeptidyl peptidase-4 (DPP-4) inactivates GLP-1 within minutes of its secretion. This was discovered in the 1990s, and it became the pharmacological rationale for DPP-4 inhibitors: block the enzyme that destroys GLP-1, and more of it survives long enough to do its job.

Sitagliptin is a selective, competitive inhibitor of DPP-4. In patients with type 2 diabetes, a single dose produces DPP-4 inhibition for a full 24-hour period. After a meal or oral glucose load, this inhibition results in a two- to three-fold increase in circulating active GLP-1 and GIP, decreased glucagon concentrations, and increased responsiveness of insulin release to glucose.

The glucose-dependence of this mechanism is the key to why sitagliptin rarely causes hypoglycemia on its own. Because GLP-1 and GIP only stimulate insulin when glucose is actually elevated, DPP-4 inhibition does not push insulin secretion when blood sugar is already in a normal or low range. The risk of hypoglycemia primarily arises when sitagliptin is combined with insulin or a sulfonylurea, agents that cause insulin release independent of glucose levels.

What the Clinical Evidence Shows

Glycemic efficacy

Across clinical trials, sitagliptin as monotherapy or add-on therapy produces HbA1c reductions of approximately 0.5 to 0.8% from baseline. That is a moderate but clinically meaningful reduction, comparable to other agents in the DPP-4 class and positioned below the reductions achieved by GLP-1 receptor agonists, which typically deliver 1.0 to 1.5% or more at higher doses. An 18-week head-to-head trial of 800 patients with inadequately controlled type 2 diabetes on metformin found saxagliptin and sitagliptin produced similar HbA1c reductions, confirming that DPP-4 agents within the class are broadly equivalent on this endpoint.

Clinical setting	Typical HbA1c reduction	Notes
Monotherapy	approximately 0.6 to 0.8%	Similar to other DPP-4 inhibitors
Add-on to metformin	approximately 0.5 to 0.7%	Most common clinical use
Add-on to insulin	approximately 0.4 to 0.6%	Allows insulin dose reduction in some patients
Add-on to sulfonylurea	approximately 0.4 to 0.6%	Increases hypoglycemia risk from the sulfonylurea; requires caution
Triple therapy (metformin plus sulfonylurea)	approximately 0.6 to 0.7%	Established combination in guidelines

The FDA approved Januvia for all of these uses. Janumet (sitagliptin 50 mg plus metformin) and Janumet XR were subsequently approved as fixed-dose combinations, simplifying the regimen for patients who need both agents. Generic Janumet is expected by May 2026 and generic Janumet XR by July 2026 per settlement terms, under certain conditions.

Cardiovascular safety: the TECOS trial and what it established

The TECOS trial (NCT00790205) was the FDA-required cardiovascular outcomes trial for sitagliptin. It enrolled 14,671 patients with type 2 diabetes and established cardiovascular disease, randomizing them to sitagliptin or placebo added to existing therapy. The primary outcome, a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina, occurred in 11.4% of sitagliptin patients versus 11.6% of placebo patients (HR 0.98; 95% CI 0.89 to 1.08; p less than 0.001 for non-inferiority). Sitagliptin was cardiovascularly safe: it neither increased nor decreased the risk of major adverse cardiovascular events.

Equally important was the heart failure finding. Sitagliptin did not increase the rate of hospitalization for heart failure. This distinguishes it within the DPP-4 class: saxagliptin in the SAVOR-TIMI 53 study showed a significant 27% increase in heart failure hospitalizations, which prompted the FDA to add a class-level heart failure warning to all DPP-4 inhibitors. That warning is on Januvia’s label, but the sitagliptin-specific TECOS data is reassuring. A re-adjudication of TECOS performed at the FDA’s request confirmed 224 heart failure hospitalization events in the sitagliptin arm and 239 in the placebo arm, numerically favoring sitagliptin. The class warning remains; the drug-specific evidence does not support the concern.

What TECOS did not show is cardiovascular benefit. Sitagliptin does not reduce cardiovascular events the way SGLT2 inhibitors and GLP-1 receptor agonists have been proven to. For patients with established cardiovascular disease, heart failure, or chronic kidney disease, the proven cardiorenal protection of those drug classes is a clinically meaningful advantage that sitagliptin does not share.

Where Sitagliptin Fits in the 2026 Type 2 Diabetes Landscape

This is the most important clinical context for understanding the Januvia LOE story in 2026. Sitagliptin is losing exclusivity at a moment when the treatment paradigm around it has shifted significantly.

The 2020s have been defined by two drug classes achieving benefits well beyond glycemic control. SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) reduce cardiovascular mortality, hospitalizations for heart failure, and progression of chronic kidney disease, benefits established in landmark outcomes trials across large high-risk populations. GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) reduce cardiovascular events, cause substantial weight loss, and in the case of semaglutide, have received FDA approval for both cardiovascular risk reduction and obesity management. The first oral non-peptide GLP-1 receptor agonist, Foundayo (orforglipron), received FDA approval in April 2026, adding a truly unrestricted oral GLP-1 option.

In that landscape, where does a weight-neutral, cardiovascularly neutral oral agent fit?

The answer is: a meaningful clinical niche that still covers millions of patients.

Drug class	CV benefit proven	Weight effect	Hypoglycemia risk (mono)	Kidney dosing	Oral option
Metformin	No (but safe)	Modest loss	Low	Reduce in CKD	Yes
DPP-4 inhibitors (sitagliptin)	No, cardiovascularly neutral	Neutral	Low	Dose reduction needed (except linagliptin)	Yes
SGLT2 inhibitors	Yes: CV, HF, kidney	Modest loss	Low	Reduced efficacy in advanced CKD	Yes
GLP-1 receptor agonists (injectable)	Yes (CV outcomes trials)	Significant loss	Low	Generally safe in CKD	No (most)
GLP-1 receptor agonists (oral)	CV trial ongoing for some	Significant loss	Low	Generally safe	Yes (semaglutide with restrictions; orforglipron without)
Sulfonylureas	No	Weight gain	Significant	Dose reduction needed	Yes
Insulin	No	Weight gain	Significant	Flexible	No

Sitagliptin’s clinical home in 2026 is patients who need a second-line oral agent that is well tolerated, has no hypoglycemia risk as monotherapy, and does not require the complexity of a GLP-1 or the cardiorenal eligibility profile that SGLT2 inhibitors require. That covers a large portion of the type 2 diabetes population, particularly older patients with multiple comorbidities where weight loss is not a primary goal, patients who cannot tolerate GLP-1 gastrointestinal side effects, and patients managed primarily in primary care settings where combination injectable regimens may not be the first choice.

The ADA Standards of Medical Care in Diabetes 2026 continues to recommend DPP-4 inhibitors as a reasonable option for patients who need additional glucose lowering with low hypoglycemia risk and no compelling indication for cardiorenal benefit.

The Safety Profile

Safety item	Details	Clinical guidance
Pancreatitis	Postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases. Causal relationship not definitively established.	Discontinue immediately if pancreatitis is suspected. Do not restart. Not recommended in patients with a history of pancreatitis.
Heart failure (class warning)	FDA class-level warning based on saxagliptin data. Sitagliptin-specific TECOS data showed no increased heart failure risk.	The class warning remains on the label but the sitagliptin-specific evidence is reassuring. Discuss with prescriber in patients with known heart failure risk factors.
Severe joint pain	Postmarketing cases of severe and disabling arthralgia reported with DPP-4 inhibitors, including sitagliptin. Onset can occur months to years after initiation.	Consider DPP-4 inhibitor as a possible cause of new-onset severe joint pain. Discontinue and reassess.
Hypoglycemia	Low risk as monotherapy. Higher risk when combined with insulin or sulfonylurea.	If combined with insulin or a sulfonylurea, lower the dose of the partnering agent to reduce hypoglycemia risk when starting sitagliptin.
Renal dosing	Sitagliptin is primarily renally excreted. Dose adjustment required for eGFR below 45 mL/min/1.73m².	Standard dose 100 mg once daily; reduce to 50 mg for eGFR 30 to 45; reduce to 25 mg for eGFR below 30. Check kidney function at baseline and periodically.
Hypersensitivity	Serious hypersensitivity reactions including anaphylaxis and angioedema reported postmarketing.	Discontinue immediately; do not restart if a hypersensitivity reaction occurred.
Bullous pemphigoid	Postmarketing reports of bullous pemphigoid (a serious skin blistering condition) with DPP-4 inhibitors.	Discontinue if bullous pemphigoid develops.

The Generic Landscape: What to Expect in 2026 and 2027

The sitagliptin generics story has two distinct threads.

Zituvio (sitagliptin free base, Zydus): FDA-approved in October 2023. Zituvio contains sitagliptin in a different chemical form (free base rather than the phosphate salt used in Januvia). It is not bioequivalent to Januvia and cannot be automatically substituted by a pharmacist, but a prescriber can write a new prescription for it specifically. At select specialty pharmacies including Marley Drug, sitagliptin in this form has been available for approximately $80 per month. This is already an accessible option for patients who know to ask about it.

True generic Januvia (sitagliptin phosphate): A generic version of Januvia was approved by Watson Labs (now Viatris) on December 30, 2025, as sitagliptin phosphate. Settlement agreements between Merck and at least 21 generic manufacturers allow launch as early as May 2026. The core Januvia patent expires November 24, 2026. When multiple generics are in the market, prices are expected to fall 80 to 85%, potentially to $50 to $100 per month.

The scale of this LOE is significant. In Q1 2026, Merck’s Januvia/Janumet franchise generated $574 million, down 28% from $796 million in Q1 2025, with the decline attributed primarily to lower pricing in the U.S. and generic competition in international markets. The U.S. decline, when it arrives fully after the November patent expiration, will be steeper.

For the broader healthcare system, the price reduction from Januvia’s LOE is among the most consequential access stories of 2026. Nearly 8 million Januvia prescriptions were filled in 2022. When per-prescription costs fall by 80 to 85%, the system-wide savings are in the billions of dollars annually, and millions of patients who have been cost-sharing or going without will have a path to affordable access.

The Janumet and Janumet XR situation

The Janumet fixed-dose combination has a slightly different patent picture. Merck’s patent covering the sitagliptin-metformin co-formulation expires in November 2026, but a separate patent on the co-formulation was defended successfully in litigation against Viatris, potentially giving Janumet XR additional protection. Settlement agreements nonetheless allow Janumet generics by May 2026 and Janumet XR generics by July 2026 under certain conditions.

For patients on Janumet, the combination’s value is primarily simplicity: one pill instead of two. When both sitagliptin and metformin are available as inexpensive generics separately, the question of whether the combination tablet justifies any remaining price premium becomes less pressing.

What This Means for Patients

If you are currently taking Januvia and your blood sugar is well controlled, nothing about your clinical situation requires you to change anything immediately. Generic sitagliptin phosphate with FDA approval is therapeutically equivalent to Januvia.

What to watch for: formulary notifications from your insurer, and conversations with your pharmacist about when generic sitagliptin becomes available on your plan’s formulary. Going from $600 a month to $80 to $100 a month for the same drug is not a minor convenience. For patients who have been managing this cost for years, it is a significant change in financial burden.

If cost has already been an issue and you have been managing with partial doses, delayed refills, or skipping months: ask your prescriber or pharmacist right now about Zituvio or authorized generic sitagliptin at pharmacies that already offer it in the $80-per-month range. You do not need to wait for the November patent expiration to access a substantially lower-cost version of this drug.

One practical note on renal dosing: generics will be available in all three strengths, 25 mg, 50 mg, and 100 mg, corresponding to the Januvia label. Patients with reduced kidney function who currently take a lower dose of Januvia should confirm that their generic prescription specifies the same strength. Dose substitution errors are a real dispensing risk when a drug transitions from brand to generic, and this is worth verifying at pickup.

For related HED coverage on diabetes treatment advances in 2026, see our post on Awiqli, the first once-weekly basal insulin for type 2 diabetes, our post on Foundayo (orforglipron), the first oral GLP-1 receptor agonist with no food or water restrictions, and our post on Langlara, the third interchangeable insulin glargine biosimilar, and what it means for insulin access.

Sources

Generic sitagliptin timeline and pricing: Januvia (Sitagliptin) 2026 Availability, Prices and Tips to Find. Medfinder. April 2026.

Merck patent settlements: Merck defends blockbuster Januvia franchise from patent challenge. Pharmaphorum. September 2022. | Merck prevails in high-stakes patent lawsuit against Viatris. Fierce Pharma. September 2022.

Merck Q1 2026 financial results: Merck Form 8-K: Januvia/Janumet Q1 2026 revenues $574 million, down 28%. SEC.gov.

Patent cliff overview: Blockbuster drugs face a massive patent cliff in 2026. Drug Discovery News. February 2026.

DPP-4 mechanism (incretin system): Ahrén B. DPP-4 Inhibition and the Path to Clinical Proof. Frontiers in Endocrinology. 2019. PMC6593050.

DPP-4 inhibitor class review: Role of DPP-4 Inhibitors in the Treatment Algorithm of T2DM. PMC6696077.

DPP-4 inhibitors (StatPearls): Dipeptidyl Peptidase IV (DPP-4) Inhibitors. StatPearls. NCBI.

GLP-1 biology: Glucagon-Like Peptide 1. StatPearls. NCBI.

TECOS trial primary publication: Green JB et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. NEJM. 2015;373:232–242. doi:10.1056/NEJMoa1501352.

TECOS trial registration: NCT00790205. ClinicalTrials.gov.

TECOS heart failure re-adjudication: Scirica BM et al. Re-adjudication of TECOS with study-level meta-analysis of hospitalization for heart failure from CV outcomes trials with DPP-4 inhibitors. Clinical Cardiology. 2022. PMC9286326.

Januvia FDA approval: FDA approves sitagliptin for type 2 diabetes. FDA.gov.

Janumet FDA approval: FDA approves sitagliptin/metformin combination tablet. FDA.gov.

Januvia prescribing information: JANUVIA (sitagliptin) Prescribing Information. Merck.

Zituvio generic availability: Generic Zituvio Availability. drugs.com.

ADA Standards 2026: Standards of Medical Care in Diabetes 2026. Diabetes Care. American Diabetes Association.

SGLT2 inhibitors overview: SGLT2 Inhibitors. StatPearls. NCBI.

Metformin: Metformin. StatPearls. NCBI.

Sulfonylureas: Sulfonylureas. StatPearls. NCBI.

Insulin: Insulin. StatPearls. NCBI.

Pancreatitis: Acute Pancreatitis. StatPearls. NCBI.

Hypoglycemia: Hypoglycemia. StatPearls. NCBI.

Diabetic kidney disease: Diabetic Kidney Disease. NIDDK.

CDC diabetes statistics: National Diabetes Statistics Report. CDC.

Empagliflozin CV benefit: FDA approves empagliflozin to reduce risk of cardiovascular death. FDA.gov.

HED internal references: Foundayo (orforglipron) FDA approval post | Awiqli once-weekly insulin post | Langlara interchangeable biosimilar insulin post

Patient resources: American Diabetes Association | Merck Patient Assistance Program | NeedyMeds | Marley Drug (low-cost generics)

Disclaimer: Health Evidence Digest provides general information about FDA approvals, loss of exclusivity events, and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about diabetes medications, including switching from brand-name to generic sitagliptin, should be made in consultation with your prescribing clinician, who can account for your full medical history, current kidney function, and other medications. Drug pricing information reflects figures at time of publication and is subject to change.

June 14, 2026

The First Needle-Free Mealtime Insulin Option for Children Just Got FDA Approval. Here Is What the INHALE-1 Data Shows, Including the Part That Is More Complicated Than the Headlines Suggest.

I have all the data including the nuanced primary endpoint story. This is one of the more interesting approval stories of 2026 because the full ITT analysis technically missed the noninferiority margin but the FDA approved based on the modified ITT. That distinction must be presented honestly and clearly. Here is the full compliant post.

The First Needle-Free Mealtime Insulin Option for Children Just Got FDA Approval. Here Is What the INHALE-1 Data Shows, Including the Part That Is More Complicated Than the Headlines Suggest.

By M. Rodriguez, CST/CMA/CCA | Health Evidence Digest

📌 The essentials On May 29, 2026, the FDA approved Afrezza (insulin human inhalation powder, MannKind Corporation) for use in children and adolescents aged 6 years and older with type 1 or type 2 diabetes. This expands Afrezza’s label beyond adults (approved June 2014) to include pediatric patients for the first time. Afrezza is the first and only inhaled mealtime insulin available to pediatric patients in the more than 100-year history of insulin therapy. The clinical basis: Phase 3 INHALE-1 trial (NCT04974528), 230 children and adolescents aged 4 to 17 years, 26-week randomized open-label comparison of Afrezza plus basal insulin versus multiple daily injections (MDI) of rapid-acting insulin analog plus basal insulin. Published in Diabetes Care, January 2026. Important nuance on the primary endpoint: the full intent-to-treat (ITT) analysis showed a between-group HbA1c difference of 0.435%, narrowly exceeding the prespecified noninferiority margin of 0.4%. This was attributed to a single non-adherent patient. A pre-specified modified ITT (mITT) analysis excluding this patient showed a difference of 0.370%, meeting noninferiority. The FDA approved based on the totality of evidence including the mITT analysis, long-term safety data, lung function data, and 20-plus years of Technosphere inhaled insulin research. Pulmonary safety: no significant difference in lung function between groups at 26 weeks. FEV1 remained within normal range throughout. No serious pulmonary adverse events. Secondary findings: significantly less weight gain and significantly higher treatment satisfaction in Afrezza-treated patients and parents versus MDI. Age minimum: 6 years and older. Price: eligible patients can access Afrezza for $35 or less per month through MannKind Cares.

Insulin has been injected for more than 100 years. Every child diagnosed with type 1 diabetes has faced the same reality: multiple daily needle sticks, in school, at meals, at sports practice, at birthday parties, at sleepovers. For most of that century, there was no alternative.

On May 29, 2026, the FDA approved Afrezza (insulin human inhalation powder) for use in children and adolescents aged 6 and older, making it the first needle-free mealtime insulin option ever available to pediatric patients. The drug that has been available to adult patients with diabetes since 2014 can now be prescribed to the children and adolescents for whom injection anxiety, school logistics, and social friction around insulin administration are documented barriers to adherence and glycemic control.

The clinical evidence behind the approval requires honest presentation. The pivotal trial technically missed its pre-specified primary endpoint in the full analysis, approved based on a modified analysis and a totality of supporting evidence. That is a fact families and prescribers deserve to understand, not a reason to dismiss a drug that addresses one of the most durable unmet needs in pediatric diabetes care.

Why Needle Anxiety in Children With Diabetes Is a Clinical Problem, Not a Parental Preference

Needle anxiety in children with diabetes is one of the most consistently documented barriers to optimal insulin therapy in pediatric endocrinology. It is not simply a matter of children disliking injections; it is a behavioral pattern with measurable downstream consequences for glycemic control.

Fear of injections drives dose skipping, delayed mealtime insulin administration, avoidance of insulin correction doses when blood glucose runs high, and in some cases refusal to initiate or intensify insulin therapy at diagnosis. In school settings specifically, the logistics of supervised insulin administration, the social visibility of the act, and the fear of peer reactions around needles create practical barriers that affect real-world glycemic management differently from how they appear in clinical trials conducted in controlled settings.

The consequences of suboptimal mealtime insulin dosing in children compound over time. Chronic hyperglycemia accelerates the development of diabetic retinopathy, nephropathy, and neuropathy. In children who spend years with elevated post-meal glucose excursions because they skip or reduce mealtime insulin doses to avoid injections, the long-term risk burden is real and well-established.

This is the clinical backdrop against which the Afrezza pediatric approval should be understood. Whether inhaled insulin achieves slightly different HbA1c values than injections in a controlled trial is relevant; whether it enables children who currently under-dose or skip mealtime insulin to take it more consistently is equally relevant, and arguably more important for the majority of real-world pediatric patients.

What Afrezza Is and How the Technosphere Delivery System Works

Afrezza is an inhaled formulation of recombinant human insulin that uses MannKind’s proprietary Technosphere drug delivery platform to achieve rapid pulmonary absorption. The drug is provided as a dry powder in a foil blister cartridge and is inhaled through a small, pocket-sized inhaler at the start of each meal.

The Technosphere platform consists of fumaryl diketopiperazine (FDKP) particles, which are engineered to form microparticles that carry insulin into the deep lung. When these particles reach the alveolar surface, they dissolve rapidly in the aqueous lung lining, releasing insulin that is then absorbed into the pulmonary capillary bloodstream. This pulmonary absorption pathway bypasses the subcutaneous tissue depot that slows absorption with injected insulin.

The pharmacokinetic result is what makes Afrezza clinically distinctive: it is the fastest-acting insulin available. In adults, Afrezza reaches peak insulin concentration within approximately 12 to 15 minutes of inhalation, compared to 55 to 90 minutes for rapid-acting injectable analogs like aspart, lispro, or glulisine. The duration of action is correspondingly shorter, approximately 3 hours, compared to 3 to 5 hours for injectable rapid-acting analogs.

Why ultra-rapid onset matters for post-meal glucose control Mealtime insulin is meant to blunt the glucose spike that follows carbohydrate absorption. For injected rapid-acting insulin analogs, there is a well-documented mismatch: the insulin starts working 15 to 30 minutes after injection but glucose starts rising almost immediately upon eating. Patients are instructed to inject 15 to 20 minutes before eating, but adherence to pre-meal injection timing is low in practice, particularly in children and adolescents in real-world settings. Afrezza’s rapid onset means it can be inhaled at the start of the meal rather than before and still reach peak effect while glucose is rising from that meal. This timing advantage is pharmacologically meaningful and practically significant in school-age children who cannot predict meal timing, must eat quickly, or cannot leave class early to administer insulin before lunch.

The INHALE-1 Trial: What the Data Shows, Including the Nuance

Design

INHALE-1 (NCT04974528) was a 26-week, open-label, randomized, multicenter Phase 3 clinical trial with a 26-week safety extension, enrolling children and adolescents aged 4 to 17 years with type 1 or type 2 diabetes. The open-label design was necessary because blinding inhaled versus injected insulin in children is not practically feasible.

Enrollment (n=230): Randomized 1:1 to:

Afrezza inhalation powder plus basal insulin (n approximately 115)
Multiple daily injections (MDI) of rapid-acting insulin analog plus basal insulin (n approximately 115)

Primary endpoint: Non-inferiority in change in HbA1c from baseline at 26 weeks, with a prespecified non-inferiority margin of 0.4%.

Lung safety monitoring: FEV1 (forced expiratory volume in 1 second) and FVC measured at baseline, 12 weeks, and 26 weeks. Serious pulmonary adverse events tracked throughout.

Key secondary endpoints: Weight change, treatment satisfaction (patients and parents), time in range (blood glucose 70 to 180 mg/dL), hypoglycemia frequency.

The primary endpoint: what happened and why it matters

This is the most clinically important and least straightforwardly reported aspect of the INHALE-1 data, and it deserves transparent presentation.

HbA1c analysis	Between-group difference (Afrezza minus MDI)	vs. 0.4% margin
Full intent-to-treat (ITT) analysis (n=230)	+0.435%	Exceeds margin — non-inferiority NOT met
Modified ITT (mITT) analysis (n=229, excluding 1 non-adherent patient)	+0.370%	Below margin — non-inferiority met

Source: INHALE-1, NCT04974528. Published Diabetes Care. January 2026. Cardiology Advisor pre-approval coverage. April 2026.

In the full ITT population, the mean HbA1c change was marginally worse in the Afrezza arm, with a between-group difference of 0.435%. This narrowly exceeded the prespecified non-inferiority margin of 0.4%, meaning the full analysis technically did not meet the primary endpoint as specified.

According to MannKind and the investigating team, this outcome was driven by a single patient who did not adhere to the study protocol. Excluding this patient in the pre-specified mITT analysis produced a between-group difference of 0.370%, which falls within the 0.4% margin, meeting non-inferiority.

The FDA approved Afrezza for pediatric use based on the totality of evidence, including the mITT analysis, 26-plus weeks of lung function data showing no meaningful pulmonary effects, 52-week safety extension data, and more than 20 years of Technosphere inhaled insulin research across thousands of patients including prior adult programs.

It is worth being direct about what this means: the FDA reviewed the evidence and concluded the benefit-risk profile supports approval. The influence of a single non-adherent patient on the ITT analysis, the pre-specified nature of the mITT sensitivity analysis, and the favorable safety, satisfaction, and weight data collectively informed that conclusion. Patients and prescribers should be aware of this nuance; it does not invalidate the approval but it is relevant context for how to weigh the glycemic control evidence.

Lung function: the key safety endpoint

Lung function parameter	Afrezza arm	MDI arm
Mean FEV1 at baseline	2.901 L (99.6% predicted)	2.948 L (102.3% predicted)
Mean FEV1 at week 26	2.934 L (96.6% predicted)	2.957 L (98.0% predicted)
Between-group difference in FEV1 change	Not statistically significant	Reference
Serious pulmonary adverse events	None reported	None reported
Normal FEV1 range maintained throughout	Yes, both groups	Yes

The lung function data is the most reassuring finding from INHALE-1 for families with legitimate concerns about what happens to a child’s lungs when they inhale insulin particles for months or years. In INHALE-1, both groups showed small declines in FEV1 percentage of predicted at 26 weeks, with no statistically significant difference between groups and both remaining solidly within normal range throughout.

No serious pulmonary complications were reported in either group over 26 weeks or through the 52-week safety extension.

Secondary endpoints: weight and satisfaction

Secondary endpoint	Finding
Weight gain at 26 weeks	Significantly less with Afrezza than MDI
Treatment satisfaction (patient-reported)	Significantly higher with Afrezza
Parent treatment satisfaction	Significantly higher for parents of Afrezza-treated patients
Hypoglycemia frequency at 26 weeks	No significant difference between groups

The weight finding is clinically meaningful. Weight gain is a documented side effect of intensified insulin therapy in children and adolescents, and excess weight gain in a pediatric diabetes population has both metabolic and psychological implications. Less weight gain with equivalent glycemic control is a genuine secondary benefit.

The treatment satisfaction finding matters for exactly the reason discussed above: a mealtime insulin option that children and parents prefer is more likely to be used consistently, particularly for the dose corrections and meal-related doses that are most commonly skipped.

The Lung Cancer Warning: What It Means and Does Not Mean for Children

Adults using Afrezza carry a warning about a potential lung cancer signal observed in adult clinical trials. This is a labeled warning that appears in the prescribing information and requires honest discussion.

The signal emerged from long-term adult trials and post-market pharmacovigilance in adults with significant histories of smoking. A causal relationship between inhaled insulin use and lung cancer has not been established. The FDA’s assessment for the adult label concluded the benefit-risk profile remained favorable for indicated adult patients while warranting the warning and ongoing monitoring.

For pediatric patients, several important contextual points apply:

The lung cancer signal, to the extent it exists, was observed in adults with long smoking histories
INHALE-1 enrolled children specifically excluding prior clinically significant pulmonary disease and requiring baseline normal lung function
No oncologic safety signals were observed in INHALE-1 or its extension
Afrezza is labeled for pediatric use starting at age 6, and the FDA reviewed pediatric-specific lung function data before granting the approval

The warning is present in the pediatric label. Parents and prescribers should be aware of it, discuss it in the context of the full benefit-risk picture for an individual child, and continue routine follow-up monitoring of pulmonary function as clinically indicated.

Safety: The Full Prescribing Information Picture

Boxed warning (applies to adult label; relevant context for pediatric prescribers):

Acute bronchospasm in patients with chronic lung disease (asthma, COPD)
Contraindicated in patients with chronic lung disease
Lung cancer signal in adults (see above)

Contraindications:

Patients with chronic lung disease including asthma and COPD (increased risk of acute bronchospasm)
During episodes of hypoglycemia
Hypersensitivity to any component of the formulation

Warnings and precautions:

Acute bronchospasm: patients should have a short-acting bronchodilator available; spirometry is recommended before initiating treatment in patients with mild or moderate lung disease
Hypoglycemia: as with all insulins, the risk of hypoglycemia requires monitoring
Hypokalemia: insulin drives potassium into cells; monitor in patients at risk
Fluid retention and heart failure (applies to combination with thiazolidinediones, not standard pediatric use)

Lung function monitoring: Perform FEV1 assessment before initiating Afrezza, every 6 months during treatment, and as clinically indicated.

Who Should and Should Not Use Afrezza

Appropriate candidates for Afrezza in the pediatric setting

Children and adolescents aged 6 and older with type 1 or type 2 diabetes who require mealtime insulin
Patients with significant needle anxiety affecting mealtime insulin adherence
Patients who frequently skip or reduce mealtime doses due to injection reluctance
Patients and families who prefer the flexibility and convenience of inhaled administration for school, social, and athletic contexts
Patients with normal baseline lung function per spirometry

Contraindicated or not appropriate

Any patient with asthma, COPD, or other chronic pulmonary disease (absolute contraindication)
Patients with FEV1 below 70% predicted (exclude from eligibility per trial criteria)
Patients with recent respiratory tract infections (hold until resolved)
Patients under 6 years of age
Afrezza is not a replacement for basal insulin and cannot be used as a basal insulin; it is a mealtime (prandial) insulin only

Practical note for younger patients (ages 6 to 7)

Afrezza administration requires the ability to use the inhaler device correctly and to exhale fully before inhalation. Children aged 6 to 7 may require more practice and caregiver supervision to ensure consistent technique. Pediatric endocrinologists and diabetes educators should assess inhaler technique specifically in younger patients before transitioning to Afrezza independently.

Dosing

Afrezza doses are based on the patient’s usual rapid-acting insulin analog dose, converted according to the prescribing information dose conversion table. The drug is available in single-use cartridges of 4 units, 8 units, and 12 units of inhaled insulin. Key dose conversion guidance (from the January 2026 label update providing starting dose guidance for patients switching from insulin pumps or MDI) is available in the full prescribing information.

Timing: inhale at the beginning of each meal. Do not use during or after a meal. Do not use for correction doses if the patient is already hypoglycemic.

Access and Cost

MannKind has announced that eligible patients can access Afrezza for $35 or less per month through its MannKind Cares patient support program. For a condition requiring daily medication for life, this cost point is a meaningful access consideration and compares favorably with list pricing for injectable rapid-acting insulin analogs prior to the insulin price cap legislation and assistance programs currently in effect.

For related HED coverage on insulin access and recent approvals, see our post on Awiqli, the first once-weekly basal insulin for type 2 diabetes, our post on Langlara and what interchangeable insulin biosimilars mean for affordability, and our post on Linzess expanding to children as young as 2 as another pediatric label expansion approval from the same week.

Sources

FDA approval announcement and MannKind press release: MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes. GlobeNewswire. May 29, 2026.

Drugs.com approval news: MannKind Announces FDA Approval of Afrezza for Children and Adolescents Aged 6 and Older. drugs.com. May 29, 2026.

AJMC clinical summary: FDA Approves Inhaled Insulin for Children, Adolescents With Diabetes. ajmc.com. May 2026.

Pharmacy Times approval coverage: FDA Approves Afrezza Insulin Inhalation Powder for Children, Adolescents With Type 1 and Type 2 Diabetes. pharmacytimes.com. May 2026.

HCPLive approval coverage: FDA Approves Inhaled Insulin Afrezza for Pediatric Patients With Diabetes. hcplive.com. May 2026.

Patient Care Online: FDA Approves First Inhaled Mealtime Insulin for Children and Adolescents With Diabetes. patientcareonline.com. May 2026.

TechTimes decision day coverage (with primary endpoint nuance): Inhaled Insulin for Children: FDA Reaches Decision Deadline for Afrezza. techtimes.com. May 29, 2026.

INHALE-1 primary publication: INHALE-1 Phase 3 results. Diabetes Care. January 2026.

INHALE-1 ADA 2025 presentation: Phase 3 INHALE-1 results presented at 85th ADA Scientific Sessions. Chicago, June 2025.

INHALE-1 trial registration: NCT04974528. ClinicalTrials.gov.

sBLA acceptance (October 2025): MannKind Announces US FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years. GlobeNewswire. October 13, 2025.

Cardiology Advisor pre-approval detailed data summary: FDA Drug Approval Decisions Expected in May 2026. thecardiologyadvisor.com. April 2026.

Afrezza original adult FDA approval (June 2014): FDA approves Afrezza to treat diabetes. FDA.gov. June 2014.

Afrezza prescribing information: Afrezza (insulin human) Inhalation Powder Prescribing Information. MannKind. 2026.

Needle anxiety and pediatric diabetes: Fear of Needles and Its Impact on Diabetes Management. PMC8261965.

Diabetic complications prevention: Preventing Diabetes Problems. NIDDK.

Patient resources: JDRF (type 1 diabetes) | American Diabetes Association: Mealtime Insulin | MannKind Cares patient support | Afrezza patient website

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Afrezza is contraindicated in patients with chronic lung disease including asthma and COPD. All decisions about mealtime insulin therapy for children and adolescents with diabetes should be made in close consultation with a pediatric endocrinologist or diabetes care team familiar with the child’s complete health history, current diabetes management, and pulmonary function status.

June 4, 2026

Another Interchangeable Basal Insulin Just Received FDA Approval. Here Is What Langlara Is, Who It Is For, and What the Access Conversation Still Needs.

The essentials: On April 29, 2026, the FDA approved Langlara (insulin glargine-aldy), a biosimilar to Lantus (insulin glargine, Sanofi) developed by Lannett Company and its subsidiary Lanexa Biologics in partnership with Sunshine Lake Pharma. It is the third interchangeable insulin glargine biosimilar approved in the United States, after Semglee (2021) and Rezvoglar (2022). Interchangeable designation: pharmacists may substitute Langlara for a Lantus prescription without calling the prescriber first, subject to state pharmacy laws. Approved populations: adults and pediatric patients with type 1 diabetes, and adults with type 2 diabetes. Clinical basis: a comprehensive analytical, preclinical, and clinical program including Phase 1 PK/PD study NCT05248841 comparing insulin glargine-aldy to insulin glargine in healthy adults. Important caveat: pricing and launch date have not been publicly announced. Whether Langlara improves real-world access for patients who currently ration insulin depends almost entirely on pricing and formulary decisions not yet made.

Approximately 8.4 million Americans require insulin to survive or to manage their diabetes. For many of them, affording that insulin is not straightforward. Lantus, the most prescribed basal insulin in the world, carries a list price of several hundred dollars per month without insurance. Published surveys estimate that 1 in 4 people with diabetes in the United States reports rationing or skipping doses because of cost.

On April 29, 2026, the FDA approved Langlara (insulin glargine-aldy), a biosimilar to Lantus developed by Lannett Company and its subsidiary Lanexa Biologics in partnership with Sunshine Lake Pharma. The approval carries an interchangeable designation, meaning pharmacists may substitute it for Lantus at the counter without contacting the prescriber first, in states that permit such substitution.

Langlara is the third interchangeable insulin glargine biosimilar approved in the United States, after Semglee (insulin glargine-yfgn) in 2021 and Rezvoglar (insulin glargine-aglr) in 2022. Whether a third entry meaningfully improves access for patients depends almost entirely on pricing and formulary decisions that have not yet been publicly announced.

What Insulin Glargine Is and Why Basal Insulin Matters

Insulin glargine is a long-acting insulin analog engineered to provide steady, predictable background insulin coverage over approximately 24 hours. The body requires two types of insulin coverage: basal, which suppresses the liver’s continuous glucose output between meals and overnight, and bolus, which handles the glucose spike that follows eating. People with type 1 diabetes produce no insulin at all and require both. Many people with type 2 diabetes eventually require basal insulin when oral medications and lifestyle changes no longer provide adequate glycemic control.

Insulin glargine (Lantus) was the first long-acting analog approved to replace older NPH insulin, which had a pronounced peak effect and required twice-daily dosing in many patients. Lantus’s flat, peakless 24-hour profile allowed once-daily dosing with lower rates of nocturnal hypoglycemia. Since its original approval in 2000, it became the most widely prescribed basal insulin in the world.

Why insulin was reclassified as a biologic, and why that matters for biosimilars Until 2020, insulin in the United States was regulated as a drug under the Federal Food, Drug, and Cosmetic Act rather than as a biologic. This meant insulin could not be approved via the biosimilar pathway under the Biologics Price Competition and Innovation Act (BPCIA), the legal framework that allows biosimilars to enter the market and compete with reference products. In March 2020, all insulin products were transitioned to biologic status under the BPCIA. This opened the regulatory pathway for true interchangeable biosimilar approvals for insulin products, with the potential for pharmacy-level substitution. Semglee became the first interchangeable insulin biosimilar in July 2021, followed by Rezvoglar, and now Langlara. The transition also means that the FDA interchangeability standard, which requires switching studies demonstrating no loss of efficacy or increase in adverse events when alternating between the biosimilar and the reference product, now applies to insulin biosimilars.

Biosimilar Versus Interchangeable: A Distinction That Matters at the Pharmacy Counter

Not all biosimilars are interchangeable, and the distinction has real consequences for how patients access the product.

	Biosimilar only	Interchangeable biosimilar
FDA standard	Highly similar to reference product; no clinically meaningful differences in safety, purity, or potency	All biosimilar standards plus: switching studies showing no greater risk than reference product when alternating
Pharmacy substitution	Cannot be substituted automatically; requires new prescription or prescriber authorization in most states	Pharmacist may substitute for the reference product without calling the prescriber, subject to state law
Patient impact	Access depends on prescriber writing specifically for the biosimilar or insurer mandating it	Patient may receive the biosimilar on a Lantus prescription without any additional action from their doctor
Langlara status	Yes	Yes, interchangeable designation granted April 29, 2026

The interchangeable designation requires manufacturers to conduct switching studies in which patients alternate between the biosimilar and the reference product at least three times, to confirm there is no loss of efficacy or increase in adverse events from switching. For Langlara, the approval was based on a comprehensive analytical, preclinical, and clinical program including Phase 1 PK/PD study NCT05248841, comparing insulin glargine-aldy to insulin glargine in healthy adults, along with the broader analytical and preclinical data package.

The Insulin Glargine Landscape: Three Interchangeable Biosimilars, One Reference Product

Product	Maker	FDA approved	Status
Lantus (insulin glargine)	Sanofi	2000	Reference product
Basaglar (insulin glargine-aglr)	Eli Lilly	2015	Biosimilar only (not interchangeable); launched 2016
Semglee (insulin glargine-yfgn)	Biocon/Viatris	2021	First interchangeable insulin biosimilar; launched at approximately $148 per 5-pack vs. Lantus approximately $340 to $520 per month
Rezvoglar (insulin glargine-aglr)	Eli Lilly	2022	Second interchangeable biosimilar; launched April 2023 at $92 per 5-pack (77% below Lantus list price)
Langlara (insulin glargine-aldy)	Lannett/Lanexa/Sunshine Lake	April 29, 2026	Third interchangeable biosimilar; pricing and launch date not yet announced

The competitive pricing history of this space is instructive. When Semglee launched as the first interchangeable biosimilar in 2021, it priced at a wholesale acquisition cost of approximately $148 per package of five prefilled pens, compared with $340 to $520 per month for Lantus without insurance. Eli Lilly’s Rezvoglar entered in April 2023 at $92 per 5-pack, setting a new low-price benchmark. Whether Langlara will compete at or below these levels has not been disclosed.

For context on how the biosimilar market is evolving in another drug class, see our post on PONLIMSI and the crowded denosumab biosimilar landscape, where 19 FDA approvals have produced only modest savings for patients due to the same rebate dynamics described below.

For related coverage of what is changing in the broader insulin landscape, see our post on Awiqli, the first once-weekly basal insulin approved for type 2 diabetes in 2026.

The Access Question: Why Regulatory Approval Is Not the Same as Affordable Access

An FDA approval of an interchangeable biosimilar is a necessary condition for improved insulin access. It is not, on its own, sufficient. The history of insulin biosimilars in the United States illustrates the gap.

Semglee launched in 2021 with a list price meaningfully below Lantus. But list prices are not what most insured patients pay: pharmacy benefit managers (PBMs) negotiate rebates with manufacturers, and those rebate arrangements often favor the originator product on formulary even when a biosimilar carries a lower list price. The result is that biosimilar insulin market penetration in the United States has grown more slowly than in Europe, where national procurement systems and institutional substitution policies have driven biosimilar adoption rates above 90% in some countries.

California’s CalRx Biosimilar Insulin Initiative offers a different model. As of January 1, 2026, CalRx-branded insulin glargine pens became available to California residents at $55 for a five-pack through a state partnership with Civica Rx and Biocon Biologics, regardless of insurance status. That price point, enabled by state procurement rather than commercial market dynamics, illustrates what becomes possible when the insulin access question is addressed as a public health problem rather than a market competition question.

For Langlara specifically, Lanexa Biologics has stated its intention to pursue broad formulary placement across all commercial channels. Whether that translates to meaningful out-of-pocket savings for the 1 in 4 diabetes patients who report difficulty affording insulin will depend on the specific list price set at launch and the formulary tier negotiations that follow.

What patients transitioning to any insulin glargine biosimilar should know No dose conversion is required when switching between interchangeable insulin glargine products. The biosimilar delivers the same clinical effect at the same dose as Lantus. Blood glucose monitoring is still recommended during any transition period, as individual insulin requirements can vary based on factors unrelated to the product switch itself. Device differences matter. Langlara is supplied as a prefilled pen. Lantus is available in both a prefilled pen and a vial. If your current regimen uses a vial and your pharmacy substitutes a prefilled pen, confirm the administration steps with your pharmacist or diabetes care team. If your pharmacist has substituted a biosimilar for Lantus, they are required by law to notify you and your prescriber of the substitution in states with such requirements. Ask your pharmacist about the specific rules in your state. If you have concerns about a substitution, you or your prescriber can request that a specific product be dispensed by noting “dispense as written” on the prescription.

Safety Profile: Consistent With the Insulin Glargine Class

As an interchangeable biosimilar, Langlara is expected to have the same clinical profile as Lantus. Warnings, precautions, and adverse reactions apply to the insulin glargine class as a whole.

Hypoglycemia: The most clinically important risk of any insulin therapy. Severe hypoglycemia can be life-threatening. Risk increases with missed meals, excessive exercise, alcohol use, renal impairment, and co-administration with other glucose-lowering agents including sulfonylureas.
Medication errors: Insulin concentration errors are a documented source of patient harm. Langlara is U-100 (100 units per mL). Never use U-100 insulin in a syringe designed for a different concentration. Do not mix insulin glargine with other insulins.
Hypokalemia: Insulin drives potassium into cells. Monitoring of potassium is important in patients at risk, including those with renal disease or on medications that lower potassium.
Hypersensitivity: Severe or life-threatening hypersensitivity reactions, including anaphylaxis, have been reported with insulin products. Discontinue and seek emergency care if systemic hypersensitivity occurs.
Thiazolidinediones (TZDs): Pioglitazone and similar drugs used alongside insulin can cause fluid retention and increase the risk of heart failure. Patients on both should be monitored for signs of fluid retention.
Injection site reactions: Lipodystrophy (skin thickening or pitting at injection sites) can develop with repeated injections at the same site. Rotate injection sites within the recommended areas (abdomen, thigh, deltoid).

What This Approval Means in Practice

Langlara’s approval adds a third interchangeable insulin glargine biosimilar to the U.S. market. The interchangeable designation is meaningful: it allows pharmacy-level substitution without a new prescription, which reduces one logistical barrier to biosimilar uptake. Whether it reduces the financial barrier depends on what Lanexa Biologics announces for pricing and formulary positioning at launch.

For patients currently on Lantus or another insulin glargine product, the most useful resources while commercial pricing evolves are the American Diabetes Association, which maintains current guidance on insulin assistance programs and state programs, and InsulinHelp.org, a nonprofit directory of insulin access resources. The JDRF also maintains updated insulin affordability resources specifically for people with type 1 diabetes.

For more on how biosimilar approvals interact with real-world access, and why regulatory clearance does not automatically translate to patient savings in the U.S. market, see our post on PONLIMSI and the denosumab biosimilar landscape.

Sources

Lannett/Lanexa/Sunshine Lake press release: Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA (insulin glargine-aldy). BioSpace. May 4, 2026.

Drugs.com approval history: Langlara (insulin glargine-aldy) FDA Approval History. drugs.com.

Drug Topics: FDA Approves Langlara as Interchangeable Biosimilar to Insulin Glargine. drugtopics.com. May 2026.

Pharmacy Times: FDA Approves New Interchangeable Biosimilar of Insulin Glargine. pharmacytimes.com. May 2026.

Endocrinology Advisor: Langlara Receives FDA Nod as Interchangeable Lantus Alternative. endocrinologyadvisor.com. May 2026.

Contemporary Pediatrics: FDA approves interchangeable insulin glargine-aldy for type 1 and type 2 diabetes. contemporarypediatrics.com. May 2026.

FDA prescribing information: LANGLARA (insulin glargine-aldy) Prescribing Information. BLA 761412. FDA.gov. 2026.

Phase 1 PK/PD study registration: NCT05248841. A Study to Assess the Pharmacokinetics and Pharmacodynamics of Insulin Glargine-ALDY Versus Insulin Glargine. ClinicalTrials.gov.

Semglee FDA approval: FDA approves Semglee, first interchangeable biosimilar insulin. FDA.gov. 2021.

Rezvoglar FDA approval: FDA approves insulin glargine-aglr (Rezvoglar). FDA.gov. 2022.

CalRx Biosimilar Insulin Initiative: CalRx. $55 per 5-pack prefilled pen. calrx.ca.gov. January 2026.

FDA interchangeable biosimilars: Biosimilar and Interchangeable Products. FDA.gov.

FDA BPCIA framework: Biosimilar Development, Review, and Approval. FDA.gov.

PBM market structure: Pharmacy Benefit Managers. PMC7748166.

Patient resources: American Diabetes Association | InsulinHelp.org | JDRF insulin affordability resources | CalRx insulin program

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. All insulin therapy decisions, including switching between products, should be made in consultation with your diabetes care provider or endocrinologist.

May 17, 2026

365 Injections a Year, or 52. Awiqli Is the First Once-Weekly Basal Insulin and the Science Behind It Is More Interesting Than the Dosing Schedule.

📌 The essentials On March 26, 2026, the FDA approved Awiqli (insulin icodec-abae, Novo Nordisk), the first and only once-weekly basal insulin in history, for adults with type 2 diabetes. 52 injections per year instead of 365. The clinical basis: four randomized, treat-to-target ONWARDS Phase 3 trials enrolling approximately 2,900 adults with T2D. Three of the four trials showed statistically superior HbA1c reduction with icodec versus daily basal insulin. The fourth met non-inferiority. A meta-analysis across five ONWARDS trials showed a mean incremental HbA1c benefit of 0.17% (95% CI 0.06 to 0.28; p=0.003). The mechanism: insulin icodec binds reversibly to albumin via fatty acid side chains, creating a circulating reservoir that releases active insulin continuously over approximately 8 days (half-life approximately 196 hours). Why the T1D indication is absent: an earlier FDA Complete Response Letter cited the higher hypoglycemia rate in ONWARDS 6 (the type 1 trial). The March 2026 approval covers type 2 diabetes only. Critical clinical consideration: icodec’s 196-hour half-life means dose adjustments take 3 to 4 weeks to reach new steady state. Titrate conservatively, no more frequently than every 1 to 2 weeks.

Basal insulin has been a cornerstone of type 2 diabetes management for decades. It works by providing a slow, steady background level of insulin that covers overnight glucose production by the liver and keeps blood sugar from rising between meals. For millions of people with type 2 diabetes who cannot achieve adequate glycemic control with oral medications alone, basal insulin is not optional. It is what keeps them safe.

But daily injections are a burden. Not a small one. A patient starting daily basal insulin at age 60 faces 365 injections per year for the rest of their life. Studies consistently show that fear of injection, injection fatigue, and the daily management burden contribute to insulin omission, dose skipping, and delayed treatment initiation, all of which translate into worse glycemic control and worse outcomes.

On March 26, 2026, the FDA approved Awiqli (insulin icodec-abae), the first once-weekly basal insulin in history, 52 injections a year instead of 365. The clinical data behind it spans five randomized trials and approximately 4,000 patients. It shows not just non-inferiority to daily basal insulin, but in several studies, superior HbA1c reduction. Understanding how that is possible, and what the trade-offs are, requires going inside the chemistry.

How Awiqli Actually Works: The Albumin-Binding Depot Mechanism

Existing basal insulins, glargine (Lantus, Toujeo, Basaglar) and degludec (Tresiba), achieve their extended duration through different mechanisms. Glargine precipitates at physiological pH, forming microcrystals that dissolve slowly. Degludec forms multi-hexameric chains that dissociate gradually from the injection site. Both produce half-lives of 12 to 25 hours, sufficient for once-daily dosing.

Insulin icodec takes a fundamentally different approach. The molecule is engineered with two fatty acid side chains that allow it to bind reversibly to albumin, the most abundant protein in blood plasma. When injected, icodec does not just sit at the injection site waiting to dissolve. It enters the bloodstream and binds to circulating albumin, which acts as a reservoir. Only a small fraction of icodec is free and active at any given time; the rest is temporarily sequestered in the albumin-bound depot. As free icodec is cleared by the body, more is released from albumin to replace it.

The result is a half-life of approximately 196 hours, about 8 days. This is long enough that a single injection provides stable, continuous insulin coverage for an entire week, with a flat pharmacodynamic profile that avoids the peak-and-trough pattern that can contribute to hypoglycemia with shorter-acting insulins.

Why the long half-life creates a specific clinical consideration The same pharmacokinetic property that enables once-weekly dosing also means that any dose adjustment takes longer to reach a new steady state. With daily insulin, a dose increase or decrease produces a measurable effect within 1 to 2 days. With icodec’s 196-hour half-life, it takes approximately 3 to 4 weeks to reach a new steady state after a dose change. This has a practical implication for titration: icodec should be titrated conservatively, with dose adjustments made no more frequently than every 1 to 2 weeks based on fasting blood glucose. Aggressive titration, adjusting every few days as some patients do with daily insulins, risks overshoot and delayed hypoglycemia. The prescribing information provides specific titration guidance that clinicians should review carefully. Similarly, if a patient is transitioning off icodec to another insulin, the insulin effect persists for several days after the last dose. Overlap with a new insulin must be carefully managed to avoid hypoglycemia during the transition period.

Why This Is a Resubmission and Why Type 1 Diabetes Is Not on the Label

The March 2026 approval is not the first time Awiqli went through FDA review. In July 2024, the FDA issued a Complete Response Letter citing two issues: concerns about the manufacturing process, and concerns about the safety of insulin icodec specifically in patients with type 1 diabetes.

The type 1 concern is worth understanding. ONWARDS 6, the Phase 3 trial evaluating insulin icodec in T1D, showed that icodec was non-inferior to degludec for HbA1c reduction. But in T1D patients, the rate of clinically significant or severe hypoglycemia was meaningfully higher in the icodec arm than in the degludec arm. The FDA’s advisory committee voted against approval for T1D, and the agency’s concerns were reflected in the CRL.

Novo Nordisk’s response was pragmatic: rather than try to address the T1D concerns in the resubmission, which would have required additional clinical data and further delayed approval, the company resubmitted in September 2025 for the T2D indication only, where the efficacy and safety data were consistently robust. That resubmission was approved in March 2026.

Novo Nordisk has stated that it remains committed to exploring icodec for type 1 diabetes and plans to conduct a new clinical trial in this population. The T1D indication is not closed; it is deferred. For now, Awiqli is approved for adults with type 2 diabetes only.

The ONWARDS Trials: What the Clinical Evidence Shows

The FDA approval is based on four trials from the ONWARDS Phase 3a clinical program, all randomized, active-controlled, and treat-to-target in design. “Treat-to-target” means that insulin doses in both arms were titrated to achieve the same blood sugar goals, a rigorous design that tests whether the drugs perform equivalently under optimized conditions.

Trial	Population	Comparator	HbA1c reduction (icodec)	HbA1c reduction (comparator)
ONWARDS 1 (78 wk, n=984)	Insulin-naive T2D on non-insulin agents	Glargine U100 (once daily)	−1.55%	−1.35%*
ONWARDS 2 (26 wk, n=526)	T2D switching from daily basal insulin	Degludec (once daily)	−0.93%	−0.71%†
ONWARDS 3 (26 wk, n=588)	Insulin-naive T2D on non-insulin agents	Degludec (once daily)	−1.57%	−1.36%†
ONWARDS 4 (26 wk, n=582)	T2D on basal-bolus regimen	Glargine U100 (once daily)	−1.16%	−1.18% (NI met)

* Superior (p less than 0.001) vs. glargine U100. † Superior (p less than 0.003 to p less than 0.0007) vs. degludec. NI = non-inferiority. Source: Published ONWARDS trials in NEJM, Lancet, JAMA, Lancet Diabetes Endocrinology.

Three of the four trials showed statistically superior HbA1c reduction with icodec compared to daily basal insulin. The fourth (ONWARDS 4, in patients already on basal-bolus regimens) met the pre-specified non-inferiority margin. A meta-analysis across all five ONWARDS trials showed a mean incremental HbA1c benefit of 0.17% (95% CI 0.06 to 0.28; p=0.003) and an odds ratio of 1.51 (95% CI 1.14 to 1.99) for achieving HbA1c below 7% with icodec versus comparators.

ONWARDS 1 also demonstrated a secondary endpoint of superior Time in Range (blood glucose 70 to 180 mg/dL) with icodec compared to glargine U100, a clinically meaningful finding given the growing emphasis on TIR as an outcome measure alongside HbA1c. Additionally, in ONWARDS 1 and 3, a higher proportion of insulin-naive patients achieved an HbA1c target below 7% without clinically significant or severe hypoglycemia with icodec versus comparators, suggesting that the once-weekly drug can deliver better glycemic control without proportionally increasing hypoglycemia burden in this population.

Dr. Julio Rosenstock, MD, Clinical Professor at UT Southwestern Medical Center and Principal Investigator of the ONWARDS trial program, characterized the approval at the time of the FDA decision as underscoring the need for new alternative insulin options that may help patients work with their healthcare providers to determine what treatment works best for them.

The Hypoglycemia Picture: Nuanced, Not Alarming

Hypoglycemia is the most important safety consideration in any insulin therapy, and the icodec data requires careful interpretation rather than a headline summary.

In insulin-naive patients (ONWARDS 1 and 3), the picture is favorable: despite achieving better HbA1c control, icodec did not generate significantly more hypoglycemia than comparators, and more patients reached target HbA1c without experiencing level 2 or level 3 hypoglycemia.

The nuance comes in the switching studies (ONWARDS 2 and 3 for patients already on insulin). Here, numerically higher rates of clinically significant (level 2) or severe (level 3) hypoglycemia were observed with icodec compared to degludec. In ONWARDS 3, rates were 0.31 versus 0.15 events per patient-year. This difference reflects a specific pharmacokinetic challenge: when patients switch from daily to weekly insulin, there is an initial period during which the full icodec depot is being established. The prescribing information recommends initiating icodec at 20% higher than the previous total daily dose for patients switching from daily basal insulin, specifically to manage this titration period.

The clinical alert on hypoglycemia in T2D Patients treated with Awiqli tended to have a greater incidence of hypoglycemia than daily comparators in some study arms, while in insulin-naive patients the rates were comparable or favorable. The key implication is that icodec requires more careful patient selection and titration guidance when used as a switch therapy versus a treatment initiation therapy. In T2D specifically, the clinical concern about hypoglycemia is lower than in T1D: T2D patients retain some endogenous insulin secretion and have counterregulatory responses that protect against severe hypoglycemia. The T1D population, where hypoglycemia was more concerning and drove the CRL, is not included in the current U.S. approval. For T2D, the FDA and the ONWARDS investigators judged the benefit-risk profile favorable.

Practical Use: Dosing, Switching, and Missed Doses

The U-700 concentration: what this means practically

Awiqli is a U-700 formulation, 700 units per mL, compared to the U-100 (100 units per mL) that most daily basal insulins use. This higher concentration is what allows a full week’s worth of insulin to be administered in a single manageable injection volume. It means that icodec is not substitutable unit-for-unit with daily insulins: a week’s dose of icodec is roughly equivalent to 7 days of the total daily dose, not a single daily dose. Careful dose calculation is required at initiation and when switching.

Starting doses and switching guidance

Patient situation	Starting approach
Insulin-naive	Start at 70 units once weekly. Titrate based on fasting blood glucose, adjusting no more than every 2 weeks.
Switching from daily basal insulin	Start at 20% higher than previous total daily basal dose, given once weekly. This accounts for the accumulation phase.
Adding to GLP-1 or oral agents	Start at 70 units weekly (same as insulin-naive). Be alert to enhanced glucose-lowering from the combination.
Patients on basal-bolus regimens	Switch based on individual assessment; the ONWARDS 4 data supports the transition in this population.

Missed dose flexibility: a genuine practical advantage

One underappreciated benefit of icodec’s long half-life is missed-dose forgiveness. Because the drug accumulates in the albumin depot and releases continuously, a missed or shifted dose is less clinically consequential than with daily insulin. The prescribing information states that if a dose is missed, it can be administered up to 3 days (72 hours) before or after the scheduled day. After administration, resume the original once-weekly schedule. This flexibility directly addresses one of the practical frustrations of daily insulin, the anxiety around a forgotten or delayed dose.

Administration

Awiqli is administered subcutaneously once weekly on the same day each week, using the Novo Nordisk FlexTouch prefilled pen. It is available in three pen sizes: 700 units per 1 mL, 1050 units per 1.5 mL, and 2100 units per 3 mL. It must not be administered intravenously, intramuscularly, or via insulin pump, and must not be mixed with other insulin products.

Safety: What the Prescribing Information Covers

The safety profile of Awiqli is broadly consistent with the basal insulin class, with the nuances around hypoglycemia and titration already discussed above.

Common adverse reactions: hypoglycemia, injection site reactions (redness, swelling, itching), lipodystrophy (skin thickening or pitting at injection sites), pruritus, rash, peripheral edema, weight gain.

Serious risks:

Severe hypoglycemia
Serious hypersensitivity reactions including anaphylaxis, angioedema, urticaria, and swelling of face and lips
Hypokalemia (low potassium, which may affect heart rhythm)

Thiazolidinediones (TZDs): Use with pioglitazone or rosiglitazone increases the risk of fluid retention and potential heart failure exacerbation. Monitor for signs of heart failure when co-prescribing.

Acute illness and fasting: During illness or significant changes in eating, blood glucose monitoring frequency should increase and dose adjustments may be needed. The long half-life means that missed or delayed doses are tolerated, but significant metabolic stress (surgery, serious illness) requires closer glucose monitoring.

Not indicated for: ketoacidosis treatment, diabetic ketoacidosis, use via intravenous or intramuscular routes, or use with insulin infusion pumps.

Why Injection Frequency Matters More Than It Might Seem

The clinical significance of moving from daily to weekly injections goes beyond convenience. The diabetes literature on insulin adherence is consistent: injection burden is one of the leading modifiable barriers to insulin initiation and continuation. “Psychological insulin resistance,” the phenomenon in which patients delay or avoid starting insulin despite clinical need, is documented in 20 to 30% of people with T2D who are recommended insulin.

Insulin omission is also common among those already on therapy: studies estimate that 20 to 50% of patients on daily basal insulin skip doses at least occasionally, with higher rates among those with greater injection frequency or complex regimens. Each omitted dose represents a period of inadequate glycemic coverage. Sustained omission accelerates the development of diabetes complications.

Once-weekly dosing does not eliminate these barriers, but it substantially reduces the number of opportunities for omission and lowers the daily psychological overhead of managing insulin therapy. Whether this translates into measurably better real-world outcomes beyond what the controlled trials demonstrated will only be known from post-marketing evidence. But the mechanistic argument is sound.

Availability and Global Status

Novo Nordisk has indicated Awiqli will be available at U.S. pharmacies in the second half of 2026. The drug has already been approved in the European Union, Canada, Australia, Japan, Switzerland, and more than a dozen other countries, in many of those markets for both type 1 and type 2 diabetes. The U.S. approval is limited to type 2 diabetes.

Pricing and formulary coverage have not been announced for the U.S. market at time of writing. Patients and clinicians should check with their insurance provider and Novo Nordisk’s patient support resources as the launch approaches. For patients on insulin experiencing cost barriers, the Novo Nordisk patient assistance program and the NeedyMeds database are useful starting points.

For related HED coverage on diabetes treatment advances and access, see our posts on the FDA approval of the first generic dapagliflozin tablets and the approval of Foundayo (orforglipron), the first oral GLP-1 pill for weight management without food or water restrictions.

Sources

FDA approval and Novo Nordisk press release: FDA approves Novo Nordisk’s Awiqli (insulin icodec-abae), the first and only once-weekly basal insulin treatment for adults with T2D. March 26, 2026. prnewswire.com.

HCPLive coverage: FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes. hcplive.com. March 2026.

Patient Care Online coverage: FDA Approves Once-Weekly Basal Insulin for Adults With Type 2 Diabetes. patientcareonline.com. March 2026.

Consultant360: FDA Approves Awiqli (Insulin Icodec-Abae) as Once-Weekly Basal Insulin. consultant360.com. March 2026.

ONWARDS 1 (NEJM): Rosenstock J et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. NEJM. 2023;389(16):1533. doi:10.1056/NEJMoa2310221

ONWARDS 2 (Lancet Diabetes Endocrinol): Philis-Tsimikas A et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in basal insulin-treated T2D (ONWARDS 2). Lancet Diabetes Endocrinol. 2023.

ONWARDS 3 (JAMA): Lingvay I et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive T2D: ONWARDS 3. JAMA. 2023;330(3):228-237.

ONWARDS 4 (Lancet): Mathieu C et al. Switching to once-weekly icodec vs once-daily glargine U100 in basal-bolus insulin-treated T2D (ONWARDS 4). Lancet. 2023.

ONWARDS 1 trial registration: NCT04508660. ClinicalTrials.gov.

ONWARDS 2 trial registration: NCT04771052. ClinicalTrials.gov.